AJP - Lung Watch the video to see how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Lung Cell Mol Physiol 292: L1182-L1192, 2007. First published February 2, 2007; doi:10.1152/ajplung.00020.2006
1040-0605/07 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
292/5/L1182    most recent
00020.2006v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reynolds, A. M.
Right arrow Articles by Reynolds, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, A. M.
Right arrow Articles by Reynolds, P. N.

Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension

Ann M. Reynolds,1,2 Wei Xia,1,2,3 Mark D. Holmes,1,2,3 Sandra J. Hodge,1,2 Sergei Danilov,4 David T. Curiel,5 Nicholas W. Morrell,6 and Paul N. Reynolds1,2,3

1Lung Research Laboratory, Royal Adelaide Hospital, 2Hanson Institute and 3University of Adelaide, Adelaide, South Australia, Australia; 4Department of Anesthesiology, University of Illinois at Chicago, Chicago, Illinois; 5Division of Human Gene Therapy, University of Alabama at Birmingham, Birmingham, Alabama; and 6Department of Medicine, University of Cambridge School of Clinical Medicine, Addenbrooke's and Papworth Hospitals, Cambridge, United Kingdom

Submitted 14 January 2006 ; accepted in final form 26 January 2007

Idiopathic pulmonary arterial hypertension (PAH) is characterized by proliferation of pulmonary vascular endothelial and smooth muscle cells causing increased vascular resistance and right heart failure. Mutations in the bone morphogenetic protein receptor type 2 (BMPR2) are believed to cause the familial form of the disease. Reduced expression of BMPR2 is also noted in secondary PAH. Recent advances in the therapy of PAH have improved quality of life and survival, but many patients continue to do poorly. The possibility of treating PAH via improving BMPR2 signaling is thus a rational consideration. Such an approach could be synergistic with or additive to current treatments. We developed adenoviral vectors containing the BMPR2 gene. Transfection of cells in vitro resulted in upregulation of SMAD signaling and reduced cell proliferation. Targeted delivery of vector to the pulmonary vascular endothelium of rats substantially reduced the pulmonary hypertensive response to chronic hypoxia, as reflected by reductions in pulmonary artery and right ventricular pressures, right ventricular hypertrophy, and muscularization of distal pulmonary arterioles. These data provide further evidence for a role for BMPR2 in PAH and provide a rationale for the development of therapies aimed at improving BMPR2 signaling.

hypoxia; growth substances; endothelium



Address for reprint requests and other correspondence: P. N. Reynolds, Dept. of Thoracic Medicine, Chest Clinic, Royal Adelaide Hospital, 275 North Terrace, Adelaide, South Australia, Australia 5000 (e-mail: paul.reynolds{at}adelaide.edu.au)




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. Lloyd Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, et al.
Cellular and Molecular Basis of Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol., June 30, 2009; 54(1_Suppl_S): S20 - S31.
[Abstract] [Full Text] [PDF]


Home page
ERRHome page
R. Souza and C. Jardim
Trends in pulmonary arterial hypertension
Eur. Respir. Rev., March 1, 2009; 18(111): 7 - 12.
[Full Text] [PDF]


Home page
CirculationHome page
L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton, D.-K. Kim, and N. W. Morrell
Altered Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease
Circulation, February 3, 2009; 119(4): 566 - 576.
[Abstract] [Full Text] [PDF]


Home page
Vet PatholHome page
C. S. Elangbam
REVIEW PAPER: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
Vet. Pathol., January 1, 2009; 46(1): 10 - 24.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
R. J. Davies and N. W. Morrell
Molecular Mechanisms of Pulmonary Arterial Hypertension: Role of Mutations in the Bone Morphogenetic Protein Type II Receptor
Chest, December 1, 2008; 134(6): 1271 - 1277.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2007 by the American Physiological Society.